

EMPLICURE INTERIM REPORT Q1, 2022

- Our objective with Amp01 is to offer an enhanced customer experience through a significantly longer release profile of both nicotine and flavor, than what exists on the market today

First quarter, 1 January – 31 March 2022

- Net revenue totalled 0.0 (0.0) MSEK
- EBIT totalled -7.3 (-0.9) MSEK
- EBITDA totalled -7.3 (-1.3) MSEK
- Cash flow totalled -5.6 (+9.5) MSEK
- Earnings per share -0.36 (-0.12) SEK

Adviser

Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via ca@mangold.se

For more information, please contact:

Torbjörn W. Larsson

CEO

Phone: +46 (0)70 747 65 99

Email: twl@emplicure.com

Erik Magnusson

CFO, Investor Relations

Phone: +46 (0)70 856 52 45

Email: erik.magnusson@emplicure.com

This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons above, on April 26, 2022 at 08:30 CET.



Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subsidiary, Amplicon AB develops consumer products, with oral nicotine as the first product. Emplicure is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com